Global Diabetic Retinopathy Treatment Market, By Treatment Type (Laser Surgery, Vitrectomy, Intraocular Steroid Injection, Anti-Vascular Endothelial Growth Factor Drug), Type (Non-Proliferative, Proliferative), Device Type (Focal Laser Treatment, Vitrectomy Devices, Scatter Laser Treatment), Severity (Mild, Moderate, Severe), Drug Type (Aflibercept, Bevacizumab, Fluocinolone, Ranibizumab, Triamcinolone Acetonide Injection), End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Diabetic Retinopathy Treatment Market
Diabetic retinopathy treatment market size is projected to grow at a compound annual growth rate of 6.35% over the forecast period of 2022 to 2029. Data Bridge Market Research report on diabetic retinopathy treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Diabetic retinopathy (DR) is basically the most common diabetic eye diseases and is leading cause of blindness in person suffering from the diabetes diseases. It is caused by fluctuations in the blood glucose levels resulting in an abnormal growth in the light-sensitive tissues present in the eye. When this fluid leaks causes macula to swell or thicken which eventually leads to vision loss.
The growing cases of diabetes among the world population as diabetes causes damage to the eyes and the favorable reimbursement policies across the globe are expected to accelerate the market growth in the forecast period of 2022 to 2029. Furthermore, the increased income and avoidance of blindness in patients and rising global geriatric population will further carve the way for the growth of the market. However, the factors such as lack of insurance and information regarding the disease is projected to restraint the market growth rate. On the other hand, the insufficient trained expertise or technically skilled ophthalmologists coupled with high treatment cost hampers the overall growth of the market. Furthermore, extended approval time for drugs is also projected to impede the overall growth of the market within the above mentioned forecast period.
In addition, the favorable government policies to make advanced healthcare services available to the masses and extensive research and development activities are likely to generate various new opportunities that will impact this diabetic retinopathy treatment market growth in the forecast period of 2022 to 2029.The lack of knowledge amongst patients in developing economies is estimated to challenge the market’s growth.
This diabetic retinopathy treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the diabetic retinopathy treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Diabetic Retinopathy Treatment Market Scope and Market Size
Diabetic retinopathy treatment market is segmented on the basis of treatment type, type, device type, severity, drug type and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment type, the diabetic retinopathy treatment market is segmented into laser surgery, vitrectomy, intraocular steroid injection and anti-vascular endothelial growth factor drug.
- On the basis of type, the diabetic retinopathy treatment market is segmented into non-proliferative, and proliferative.
- On the basis of device type, the diabetic retinopathy treatment market is segmented into focal laser treatment, vitrectomy devices and scatter laser treatment.
- On the basis of severity, the diabetic retinopathy treatment market is segmented into mild, moderate and severe.
- On the basis of drug type, the diabetic retinopathy treatment market is segmented into aflibercept, bevacizumab, fluocinolone, ranibizumab and triamcinolone acetonide injection.
- Based on end user, the diabetic retinopathy treatment market is segmented into hospitals, ophthalmic clinics and ambulatory surgical centers.
Diabetic Retinopathy Treatment Market Country Level Analysis
Diabetic retinopathy treatment market is analyzed and market size information is provided by treatment type, type, device type, severity, drug type and end user as referenced above.
The countries covered in the diabetic retinopathy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the diabetic retinopathy treatment market due to the high market penetration of Avastin, Eylea and Lucentis which are anti-VEGF drugs, largest share owing to the supportive reimbursement policies and increasing prevalence of diabetes in this region. Asia-Pacific region, on the other hand is expected to expand at a significant growth rate because of the high healthcare expenditure, surging geriatric population and rising disposable income. Moreover, growing usage of Lucentis is expected to drive market growth in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Diabetic retinopathy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Diabetic Retinopathy Treatment Market Share Analysis
Diabetic retinopathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to diabetic retinopathy treatment market.
Some of the major players operating in the diabetic retinopathy treatment market report are Bayer AG, Digital Diagnostics Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Oxurion NV., Genentech, Inc., Regeneron Pharmaceuticals Inc., Sirnaomics, Inc., Allergan, Abbott, Bausch Health Companies Inc., Kowa Company, Ltd., Alimera Sciences., Glycadia, Inc., Ampio Pharmaceuticals Inc., Sirnaomics, Inc., IRIDEX Corporation, Lumenis Be Ltd., and Valon Mortgage, Inc., among others.
Customization Available : Global Diabetic Retinopathy Treatment Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.